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  21 
	Synopsis 22 
The current state of antibiotic discovery, research and development is insufficient to respond to the 23 
need for new treatments for drug-resistant bacterial infections.  The process has changed over the 24 
last decade with most new agents in phases 1-3, or recently approved, having been discovered in 25 
small and medium-sized enterprises (companies; SMEs) or academia.  These have then been 26 
licensed or sold to large companies for development with the end goal of taking them to market.  27 
However, early drug discovery and development, including the possibility of developing previously 28 
discontinued agents would benefit from a database of antibacterial compounds, to be scrutinised 29 
by the developer.  This article describes the first free, open-access searchable database of 30 
antibacterial compounds, including discontinued agents, drugs under pre-clinical development and 31 
those in clinical trials: AntibioticDB (AntibioticDB.com).  Data were obtained from publicly 32 
available sources. This article summarises the compounds and drugs in AntibioticDB including 33 
their drug class, mode of action, development status and propensity to select drug-resistant 34 
bacteria.  AntibioticDB includes compounds currently in pre-clinical development and 834 that have 35 
been discontinued and that reached varying stages of development.  These may serve as starting 36 
points for future research and development. 37 
 38 
  39 
	Introduction 40 
In 2009, the WHO declared antibiotic resistance one of the biggest threats to mankind.1  One 41 
answer to the crisis seems simple: to generate new antibiotics.  However, it takes approximately 42 
10-15 years from the discovery of a compound, to progress through pre-clinical and clinical 43 
development before a medicine can be licensed and then marketed.2  Furthermore, the average 44 
expenditure required to research and develop a compound is estimated at ~$350 million3 (not 45 
including failures which can increase the cost to ~$5 billion)4.  This cost could bankrupt a small or 46 
mid-size company.  Once an antibiotic has been discovered, data must be provided to show a 47 
safety profile suitable for human testing.  This pre-clinical development phase typically provides 48 
animal pharmacokinetic data, toxicity profiles and efficacy against the bacterial target. 49 
Before compounds can be tested in human clinical trials, an institution must apply to the 50 
appropriate national or regional drug regulatory authority indicating that, based upon pre-clinical 51 
data, the drug is deemed safe to be tested in humans.  In the USA, an Investigational New Drug 52 
(IND) application from the United States FDA must be granted before testing can commence.  A 53 
similar process exists for the EU via the EMA, and in Japan and China.  Typically, 17.3% of 54 
antimicrobial compounds in pre-clinical development proceed to phase 1 clinical trials.2  Once an 55 
IND application has been granted, pre-marketing clinical trials are split into three phases (Table 1). 56 
There is no doubt that the antibiotic pipeline needs revitalisation; however, the answer may not 57 
only be the development of new drugs, but also re-investigating compounds previously 58 
discontinued.  Unfortunately, no database exists that collectively records the discovery of 59 
compounds and those in pre-clinical and clinical development with those that did not become 60 
approved drugs, or the reasons for the lack of development or approval. There is an existing 61 
database of microbial compounds, but this only provides chemical and physical data on some 62 
drugs.5 63 
This article describes the first publicly accessible free database of antibacterial compounds, 64 
AntibioticDB.  This includes links to data on discovery, research and clinical trials, those awaiting 65 
approval from the FDA/EMA and discontinued compounds.  AntibioticDB aims to serve as a 66 
platform for future research, antibiotic discovery and development. 67 
	  68 
	Methods 69 
Sources of antibacterial compounds 70 
Compounds and drugs were identified by reading material from numerous sources including from 71 
(1) the ASM Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) or 72 
European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) conferences from 73 
1961 to 2016; (2) Journal of Antimicrobial Chemotherapy, Antimicrobial Agents and 74 
Chemotherapy, Journal of Medicinal Chemistry, and Bioorganic and Medicinal Chemistry Letters; 75 
(3) Google patent searches (https://patents.google.com) with the search terms ‘antibiotic’ and 76 
‘antibacterial’. Additional names of compounds and drugs were obtained by discussion with key 77 
opinion leaders who had worked in the Pharmaceutical industry. Once names had been obtained, 78 
information on each compound/drug was obtained by additional internet searches e.g. on PubMed. 79 
Where available, links to published abstracts are included in AntibioticDB.  For abstracts before 80 
2013, the year the compound was first described is indicated.  Wherever possible, any compound 81 
described in pharmaceutical or biotech company literature or website and/or by research institutes 82 
and/or universities has also been included.  If a compound has been developed by an organisation 83 
with a website that details the current status of the compound, this website is listed.  If a compound 84 
has been patented, the web address is indicated regardless of whether the patent has expired or 85 
not.  Information regarding drug patents was primarily obtained by Google’s patent search feature.  86 
Drugs in clinical trials included in AntibioticDB were not limited to those only under FDA or EMA 87 
approval, but also included outside drug monitoring organisations such as, but not limited to, the 88 
Pharmaceuticals and Medical Devices Agency, Japan (PMDA).  Table 2 shows the definitions of 89 
terms used in AntibioticDB.  Bracketed compounds in AntibioticDB represent the most promising 90 
compounds of a series of analogues.  Information on the inferior derivative compounds can often 91 
be found in the reference provided. 92 
Limitations of AntibioticDB 93 
The current focus of AntibioticDB is compounds active against Gram-positive and/or negative 94 
bacteria; compounds that target Mycobacterium tuberculosis are not currently included.  It is 95 
intended that AntibioticDB will be continually updated and extended.  Individuals and organisations 96 
	are invited to contribute information subject to peer review by BSAC.  AntibioticDB has a short 97 
web-based form to facilitate this process. 98 
In contrast to the abstracts presented after 1990, in the earlier years of ICAAC, very few of the 99 
presented abstracts were uploaded in full to the internet, meaning that available data on some of 100 
the compounds is very scarce.  In this case, AntibioticDB serves as a platform for interested 101 
parties to contact original authors to obtain information directly that cannot be found elsewhere in 102 
the literature. 103 
104 
	Results 105 
 106 
AntibioticDB, comprises two types of data.  Firstly, antibacterial compounds in current development 107 
and for which data has been published since April 2013.  This information is indicative of the 108 
current antibiotic development pipeline.  Secondly, compounds described between 1961 and 31st 109 
March 2017 that were discontinued at varying stages of development.  There are 147 pre-clinical 110 
compounds listed currently under research and/or development; 77 have some activity against 111 
Gram-negative bacteria.  Only six of these compounds state they specifically target MDR Gram-112 
negative infections; examples include NAB-739, a polymyxin derivative (Northern Antibiotics) and 113 
FSI-1686 a carbapenem (Merck & Co.).  Some companies have focused on creating analogues of 114 
pre-existing compounds with a better pharmacology profile than predecessor compounds of the 115 
same class.  As a result, some novel compounds are being developed that belong to pre-existing 116 
drug classes.  Kibdelomycin, a type II topoisomerase inhibitor (Merck & Co), targets C. difficile 117 
infections and has a low propensity to select resistant bacteria.6  Nabriva Therapeutics has an on-118 
going pre-clinical programme investigating extended spectrum pleuromutilins (ESPs), specifically 119 
aimed at Gram-negative bacteria.7 120 
Data from AntibioticDB demonstrates that as of 31 March 2017, there were 53 compounds in 121 
active research and development: 12 in phase 1, 20 in phase 2, 19 in phase 3, and 2 in pre-122 
registration.  A few compounds in clinical trials are claimed to display novelty in their field with 123 
unique modes of action that currently display no modes of resistance.  For instance, brilacidin is a 124 
member of a new class modelled on host defence proteins (HDP-mimetics); (defensin mimetics).  125 
Two antimicrobial peptides are in clinical trials: LTX-109 (Lytixar™, Lytix Biopharma) and 126 
Pexiganan™ (Dipexium Pharmaceuticals); both are topical agents for Gram-positive infections.  127 
Radezolid (Melinta Therapeutics, USA) is an oxazolidone currently in phase 2 that has shown 128 
successful results against uncomplicated skin and skin-structure infections (uSSS) and 129 
community-acquired pneumonia (CAP).  There are currently 834 discontinued compounds in 130 
AntibioticDB, some of which are available to purchase for research. 131 
	Compounds in AntibioticDB  132 
Aminoglycosides (20 in AntibioticDB) 133 
Aminoglycosides are broad-spectrum agents derived from Streptomycetes natural products and 134 
contain amino sugar subgroups.  Their act via inhibition of protein synthesis through binding to the 135 
ribosomal 30S subunit.  There are currently two listed in AntibioticDB currently in research and 136 
development, one in pre-clinical and one in phase 3 trials.  FY-901, currently in pre-clinical 137 
development by Changzhou Fangyuan Pharmaceutical, China, is being developed to treat MRSA.  138 
Achaogen, USA, has developed plazomicin (ACHN-490) an aminoglycoside with Gram-negative 139 
activity including multidrug-resistant Enterobacteriaceae.  Following results from two phase 3 140 
studies, EPIC (urinary tract infections (UTIs)) and CARE (bacteraemia), Achaogen expect to 141 
submit  a New Drug Application in the USA and a Marketing Authorization Application (MAA) in 142 
Europe during 2017/8.8  The development of 18 aminoglycosides was discontinued, many due to 143 
intolerable levels of toxicity.  One example is TS2037 (Meiji Seika Pharma., Japan), a derivative of 144 
arbekacin, which showed good in vitro broad-spectrum activity, but was discontinued because of 145 
its high levels of nephrotoxicity. 146 
Anthracyclines (Three in AntibioticDB) 147 
Anthracycline IT-62-B was reported by Taisho Pharmaceuticals (Japan) as having Gram-positive 148 
activity.  Consistent with the current use of anthracyclines as anti-tumour chemotherapeutics,9 this 149 
molecule was discontinued as an antibacterial due to its cytotoxicity in humans. 150 
Antibodies (Eleven in AntibioticDB) 151 
Antibodies are immune effector molecules that identify and begin the cascade leading to 152 
eradication of foreign material (including bacteria).  This is achieved by opsonisation of the target 153 
bacteria by cells of the immune system.  Attenuation of pathogenic bacteria can be by directly 154 
blocking a bacterial component essential to virulence (e.g. adhesins or toxins) through binding of 155 
specific monoclonal antibodies.  These differ from the mechanisms of action of typical antibiotics, 156 
suggesting that cross resistance is unlikely, making monoclonal antibody therapy an attractive 157 
option for treatment of bacterial disease.10  An example of an indirectly neutralising antibody in 158 
	AntibioticDB is Thravixa (Emergent Biosolutions,USA), which targets the Bacillus anthracis toxin, 159 
reducing the ability of the bacterium to cause disease.11  Studies in rabbits, and phase 1 clinical 160 
trials indicate that the antibody is well-tolerated and decreases mortality rates in the animal model.  161 
Further identification of novel, highly-conserved bacterial targets for antibody therapy is required to 162 
render these technologies a viable therapeutic option. 163 
Antimicrobial peptides (AMPs) (60 in AntibioticDB) 164 
AMPs are naturally-occurring peptides, often present in the innate immune system, that 165 
demonstrate antibacterial activity, and are evolutionarily conserved with a diverse range of 166 
functions.  They are not only effective as antibiotics but also demonstrate activity against fungi and 167 
viruses.12  Most AMPs act against bacteria via membrane permeabilisation, which is possible due 168 
to the AMP’s amphipathic structure, allowing them to bind to, and penetrate, bacterial membranes.  169 
Unfortunately, most AMPs have toxicity issues, hampering their development into therapeutic 170 
drugs.13  One of the main problems with AMPs derived from human immune effectors is the risk 171 
that bacteria may become resistant thus making the immune system redundant.  Creating semi-172 
synthetic AMPs using prediction models can help reduce toxicity and improve efficacy14 as well as 173 
generate variation in the AMP structure.  However, due to poor pharmacokinetics of many AMPs, 174 
they have been limited to exploration as topical applications.15  Of the 60 listed, research into 23 is 175 
no longer active.  Thirty-seven products are in active pre-clinical development including agents 176 
with activity against both Gram-negative and Gram-positive bacteria.  AA-139 (Arenicin), 177 
developed by Adenium Biotech, Denmark, is currently in pre-clinical development and shows 178 
activity against a variety of Gram-negative bacteria including Escherichia coli, K. pneumoniae, P. 179 
aeruginosa and A. baumannii.  NAI-603, developed by NAICONS, Italy and NAI-107 developed by 180 
Sentinella Pharmaceuticals, Inc. (previously owned by NAICONS), are both currently in pre-clinical 181 
development for MRSA.  Two AMPs, Lytixar (LTX-109 by Lytix Biopharma, Norway) and 182 
Pexiganan by Dipexium Pharmaceuticals (DPRX) are currently in phase 2 and 3, respectively, for 183 
topical administration. 184 
Defensins are a cationic subgroup of AMPs which play a crucial role in innate bacterial immunity.16  185 
Due to the defensin’s cationic (positive) charge they can bind to negatively-charged bacterial 186 
	membranes, producing pore-like structures and enhancing permeability. Brilacidin (Cellceutix, 187 
USA), a defensin-mimetic compound is currently in clinical trials for a wide-range of non-infective 188 
clinical indications including ulcerative colitis and mucositis in addition to phase 2 clinical trials of 189 
acute bacterial skin and skin structure infections (ABSSSI), results of which demonstrated non-190 
inferiority to daptomycin.17  Celluceutix is investigating Bilacidin and similar compounds pre-191 
clinically for the management of Gram-negative and fungal infections. 192 
Bacteriocins are AMPs produced by bacteria to defend against competing prokaryotes.  Academia 193 
has primarily focused on the lantibiotics, which facilitate their action by inhibiting cell wall 194 
biosynthesis leading to membrane instability and cell death.18  Therapeutic use has been 195 
hampered by their narrow spectrum, expense of production and limited tissue distribution.  196 
AntibioticDB contains examples of several compounds that could serve as a scaffold for 197 
optimisation and development into therapeutic drugs.  For example, Asahikasei Pharma Corp., 198 
Japan was developing API7444 for the treatment of MRSA and penicillin-resistant Streptococcus 199 
pneumoniae.  While this compound showed potent activity in vitro, its activity against MRSA in 200 
mouse models was markedly lower than that of existing treatments and so the compound was 201 
discontinued in 2004.19 202 
Bacteriophage endolysins (15 plus four bacteriophage delivery systems in AntibioticDB) 203 
Endolysins (or lysins) are hydrolytic enzymes produced by bacteriophages that target the 204 
peptidoglycan layer of bacteria triggering lysis.  Several potential candidate compounds such as 205 
CF-301 has completed phase 1 (ContraFect, USA).  This compound is under development for the 206 
treatment of resistant S. aureus bloodstream infections.  Phico Therapeutics have developed a 207 
novel bacteriophage engineered to deliver a DNA-binding protein with cidal antibacterial action.  208 
Their first product to enter clinical trials is SASPject™ PT1.2, studied in the treatment of S. aureus-209 
related infections.  Phico have further products in pre-clinical studies for the treatment and 210 
management of Pseudomonas, Klebsiella and E. coli infections.  Fifteen further compounds are 211 
listed in pre-clinical development with activity mainly against Gram-positive bacteria.  The only 212 
exception is PlyF307 (Laboratory of Bacterial Pathogenesis and Immunology, The Rockefeller 213 
	University, New York, New York, USA) that demonstrated activity against A. baumannii biofilms 214 
both in vitro and in vivo.20 215 
Endolysins are ineffective against Gram-negative bacteria since their outer membrane prevents 216 
access to the peptidoglycan wall.21  A novel approach to circumvent this problem is to combine 217 
endolysins with an antimicrobial peptide in order to breach the outer membrane.  One example is 218 
Art-175 (Laboratory of Gene Technology, KU Leuven, Belgium), which combines an endolysin with 219 
a targeting peptide that transports the endolysin through the outer membrane of Gram-negative 220 
bacteria.  Art-175 demonstrated potent activity against P. aeruginosa,22 suggesting potential in the 221 
development of future therapies. 222 
In addition to the use of therapeutic phage lysins, whole bacteriophage therapy has long been 223 
considered a potential treatment for antimicrobial-resistant infections.  While this has gained 224 
traction in some parts of the world, further development is required, especially with the potential for 225 
bacteria to develop phage resistance.23 226 
Beta-lactam antibiotics (220 in AntibioticDB) 227 
Beta-lactams are a broad class, all containing the characteristic four-membered lactam ring, and 228 
include: carbapenems, cephalosporins, monobactams and penicillins.  Their action is facilitated 229 
through interaction with penicillin-binding proteins (PBPs), enzymes involved in peptidoglycan and 230 
cell wall biosynthesis, causing cell lysis through weakening of the peptidoglycan layer.  The 231 
foremost resistance determinant for this class of drugs is deactivation by bacterial beta-232 
lactamases. 233 
There are 47 carbapenems listed; four are under active investigation, two are in pre-clinical studies 234 
and two are in clinical trials. In pre-clinical investigations FSI-1671 and FSI-1686 (Achillon/FOB 235 
Synthesis) have demonstrated efficacy against Gram-negative bacterial infections.24  Imipenem 236 
with relebactam (MK-7655) (Merck, USA) is a carbapenem/beta-lactamase inhibitor combination 237 
that is currently moving into phase 3 clinical trials for the management of hospital-acquired and 238 
ventilator-acquired pneumonia and against imipenem resistant infections.  In 2016, a phase 3 239 
study of the meropenem-vaborbactam (another carbapenem-beta-lactamase inhibitor) combination 240 
	product (Medicines Company, USA) in complicated UTIs was carried out. In February 2017, a New 241 
Drug Application (NDA) was filed with the FDA. 242 
Of the 98 cephalosporins listed in AntibioticDB only four remain in active development.  243 
Cephalosporins are semi-synthetic agents based on the natural product produced by 244 
Cephalosporium acremonium.  Two of the four cephalosporins listed are currently in pre-clinical 245 
development.  The fate of one of these products is however unsure; CB-027 a cephalosporin was 246 
in the Cubist Pharmaceuticals programme and had demonstrated broad-spectrum activity against 247 
several drug-resistant strains including MRSA, P. aeruginosa and K. pneumoniae.25  Following the 248 
takeover of Cubist by Merck no evidence can be found that development of this product is 249 
continuing.  Two further cephalosporin-containing products cefiderocol (a siderophore 250 
cephalosporin) and the combination ceftaroline/avibactam are currently in phase 3.  Currently there 251 
is only one licensed monobactam in clinical use, aztreonam. A combination product of 252 
aztreonam/avibactam is currently in active development in phase 2. 253 
Two hundred and three beta-lactams (including combination products) have been identified which 254 
are no longer the focus of active research and development.  These include 43 carbapenems, 98 255 
cephalosporins, 15 monobactams and 14 penicillins. 256 
Efflux inhibitors (13 in AntibioticDB) 257 
Efflux pumps are trans-membrane proteins that can extrude diverse substrates, and constitute one 258 
of the most common mechanisms underlying intrinsic drug resistance;26 inhibiting their activity 259 
increases bacterial susceptibility to the compounds extruded.  MBX 2319 (Microbiotix Inc, USA) a 260 
pyranopiridine compound in pre-clinical studies inhibits the action of the E. coli AcrB multi-drug 261 
resistance efflux pump.  AcrB can extrude a wide array of antibiotics including chloramphenicol, 262 
fluoroquinolones and beta-lactams.  Use of inhibitors should restore activity to these drugs.  263 
Optimisation of the molecular scaffolds of these inhibitors for enhanced efficacy and species 264 
specificity is under active research.  265 
Development has stopped for the eleven remaining compounds.  One, MC-04124, was only 266 
discontinued following the closure of Essential Therapeutics, who were developing several efflux 267 
inhibitors.  Molecules such as these may make good candidates for continued development. 268 
	Fab inhibitors (Twelve in AntibioticDB) 269 
Bacterial fatty acid synthesis (FAS-II) is maintained by a series of mono-functional enzymes that 270 
make up the FAS-II pathway.  FabI or Enoyl–ACP reductase, is a key enzyme in the final steps 271 
and is conserved throughout most bacterial species.  There are eight FabI inhibitors undergoing 272 
investigation, with four currently in clinical trials.27-29  Debio1450, Debio1452 (Group, Switzerland) 273 
and CG-400549 (CrystalGenomics, South Korea) are currently in phase two and being developed 274 
for the treatment of acute bacterial skin and skin structure infections. FAB001/MUT056399 (Fab 275 
Pharmaceuticals, India) is a narrow-spectrum FabI inhibitor being developed against MRSA.27  The 276 
four FabI inhibitors currently in pre-clinical development are mostly aimed at Gram-positive 277 
bacterial infections with the exception of PT52 and PT68 (Diphenyl ethers) (Department of 278 
Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA), 279 
which has demonstrated activity against the Gram-negative bacteria Burkholderia pseudomallei.30 280 
FtsZ inhibitors/cell division inhibitors (Two in AntibioticDB) 281 
FtsZ is the earliest protein involved in bacterial cytokinesis, its closest homologue in eukaryotic 282 
cells is tubulin; there is interest in utilising FtsZ and other crucial proteins in the bacterial cell 283 
division pathway as potential targets.31  AntibioticDB contains two FtsZ inhibitors, TXA-709 and 284 
PC190723, both in pre-clinical development with Taxis Pharmaceuticals incorporated.  285 
Glycopeptides (including lipoglycopeptides) (29 in AntibioticDB) 286 
Glycopeptides are glycosylated non-ribosomal peptides, comprising both natural and semi-287 
synthetic products, showing activity against Gram-positive bacteria.  They bind to a fragment of the 288 
outer peptidoglycan layer, D-alanyl-D-alanine, causing inhibition of transglycosylation and 289 
transpeptidation, disrupting cell wall synthesis and leading to cell lysis and death.  Due to poor 290 
permeability and active efflux, glycopeptides have limited activity against Gram-negative bacteria.  291 
We include lipoglycopeptides, which are semisynthetic compounds produced through the addition 292 
of a lipophilic side chain to the glycopeptide base.  Currently there is one agent in pre-clinical 293 
development, three in clinical development. In addition, telavancin, dalbavancin and oritavancin 294 
have recently received marketing approval.  Ramoplanin (Nanotherapeutics, USA) and TD-1607 295 
are currently in phase two and one, respectively. TD-1607, a glycopeptide-cephalosporin hybrid, is 296 
	being tested in the management of acute bacterial skin and skin structure infections and 297 
ramoplanin is being tested for the treatment of Clostridium difficile.32 298 
Development of 23 glycopeptides in AntibioticDB has been discontinued.  Following the takeover 299 
of Wyeth by Pfizer AC98-6556, their ‘cell wall synthesis inhibitor’ research programme was 300 
discontinued in 2009. 301 
Lincosamides (three in AntibioticDB) 302 
Lincosamides inhibit protein synthesis by affecting the assembly of the 30S ribosomal complex.33  303 
AntibioticDB contains three lincomycin analogues and derivatives, with very little academic pursuit 304 
beyond discovery.  Most of these compounds had adverse toxicological effects in humans, 305 
although these were not directly cited as the reason for discontinuing research.  Examples include 306 
rancomycin 1 and 2,34 which showed potent broad-spectrum activity, but were discontinued at the 307 
preclinical stage due to toxicity. 308 
Lipopeptides (Seven in AntibioticDB) 309 
With discovery of daptomycin (1986), lipopeptides represent the latest antibiotic class to be 310 
approved.  They consist of linear or cyclic peptides with a fatty acid group covalently linked to the 311 
N-terminus.  It is thought that they bind to the bacterial cytoplasmic membrane and aggregate.  312 
One lipopeptide, surotomycin (Cubist), was in phase 3, testing its use against C. difficile-313 
associated diarrhoea; however, the programme stopped following acquisition of Cubist by Merck. 314 
LptD/Imp inhibitor (one in AntibioticDB) 315 
Murepavadin (POL7080 Polyphor, Switzerland) is currently in phase two. It is a protein epitope 316 
mimetic LptD inhibitor being developed for the treatment of P. aeruginosa ventilator-associated 317 
bacterial pneumonia, lower respiratory tract infections and bronchiectasis.35 318 
Macrolides and Macrocycles (59 in AntibioticDB) 319 
These agents are based on naturally-occurring polyketides, produced by bacteria such as 320 
Micromonospora.36  The macrolide ring gives the compounds their antibacterial functionality and 321 
allows reversible binding to the 50s ribosomal subunit.  Three macrolides are currently under 322 
active investigation.  Solithromycin (Cempra Inc.) has completed phase three for community-323 
	acquired pneumonia,37 however its ‘new drug application’ to the Food and Drugs Administration 324 
(FDA) in the US was rejected in December 2016.  Before a re-application can be made the FDA 325 
requested further clinical safety information and assurances on the manufacturing facility.  A 326 
second macrolide, nafithromycin (Wockhardt) will shortly be entering phase 2 for the treatment and 327 
management of community-acquired pneumonia.  RBx 14255 (Department of Infectious Diseases, 328 
New Drug Discovery Research, Ranbaxy Research Laboratories, R & D, Gurgaon, India) is 329 
currently in pre-clinical development for the treatment of infection by macrolide-resistant 330 
Streptococcus pneumoniae. 331 
Fifty-six macrolides in AntibioticDB were discontinued (24 categorised as ketolides and four 332 
azolides) many due to adverse toxic effects in humans or inferior activity to similar, already 333 
marketed compounds.  Several macrolides were also discontinued due to poor stability in vivo.  334 
One example is difficidin (Merck & Co., USA), which, despite showing broad-spectrum activity 335 
against aerobic and anaerobic bacteria, was unstable at differing pHs and easily oxidised.  This 336 
drug showed little activity in a mouse model when administered subcutaneously, but was highly 337 
effective when administered through intraperitoneal injection, suggesting that metabolism 338 
prevented it from reaching the infection site. 339 
Moenomycins (One in AntibioticDB) 340 
Moenomycins act through direct inhibition of peptidoglycan glycosyltransferases, which are crucial 341 
in the last stages of bacterial cell wall synthesis.  Research into therapeutic use has been limited 342 
due to suboptimal pharmacokinetics, but they represent an attractive scaffold for antibiotic 343 
discovery and development.  They have recently been shown to be active against multi-drug 344 
resistant Helicobacter pylori.38 345 
Nanoparticles (Three in AntibioticDB) 346 
Nanoparticles are between 0.1 and 100 nm; their small volume to surface area ratio gives them 347 
unique properties that can be manipulated to target specific bacterial components via novel 348 
mechanisms.  In 2011 IBM developed ‘ninja particles’, which were biodegradable nanoparticles 349 
that could target MRSA, and act through a similar mechanism as some immune effectors.  These 350 
	ninja particles target the membrane and cause instability, resulting in lysis.  There was also a low 351 
propensity to select for resistance.39 352 
It is well-documented that metal alloys have antibacterial properties,40 and two nanoparticles 353 
derived from heavy metals are in pre-clinical development for the treatment of infectious disease, 354 
including both silver (nano-Ag) and gold (nano-Au) nanoparticles.  Nano-Ag’s antimicrobial action 355 
is mediated by its binding to the bacterial cell membrane causing dissipation of proton motive force 356 
and membrane instability.41  Gold nanoparticles appear to have a more diverse mechanism of 357 
action; they have been shown to inhibit the tRNA-binding ribosomal subunit and also to inhibit the 358 
action of ATP synthase, having a deleterious effect on bacterial metabolism.42  Gold nanoparticles 359 
have also been shown to increase chemotaxis and have subsequent potential to be used in drug-360 
delivery systems.43  An issue with nanoparticles can be their efficacy in the presence of serum, as 361 
serum-protein interactions dissipate nanoparticle activity.  Gnanadhas et al.44 have demonstrated 362 
that by citrate-capping silver nanoparticles, their interaction with serum proteins could be reduced.  363 
This reduction also correlated with a higher cell uptake of free nanoparticles, thereby increasing 364 
efficacy and antibacterial activity. 365 
Nitrofurans (two in AntibioticDB) 366 
Nitrofurantoin and furazolidone are currently the only nitrofurans licensed for therapeutic use.  367 
Recent studies have shown that nitrofurantoin may be a candidate for revival in the treatment of 368 
ESBL-producing E. coli lower UTIs,45 implying that nitrofurans may be a good base for future 369 
redevelopment for treatment of susceptible organisms resistant to first line antibiotics.  One 370 
example from AntibioticDB is AS17665, which was discontinued by Abbott Laboratories in 1962.  371 
While the exact reason for discontinuation is unclear, the antibiotic was shown to be primarily 372 
active against tumours, and hence toxicity is a possible concern.  Despite this, the compound was 373 
shown to be active against S. aureus, Streptococcus pyogenes, E. coli and Salmonella 374 
Typhimurium. 375 
Oxazolidinones (80 in AntibioticDB) 376 
Oxazolidinones (e.g. linezolid) display antibacterial activity against Gram-positive bacteria, but 377 
have poor anti-Gram-negative efficacy.  Their mechanism is via inhibition of protein synthesis 378 
	through binding to the P-site of the ribosomal 50S subunit.  Currently, four out of the six active 379 
oxazolidone compounds listed in the AntibioticDB are in clinical development.  MRX-II (MicuRx 380 
Pharmaceuticals, USA) is one of two listed oxazolidinones in pre-clinical development,46, 47 381 
however any information concerning its development has not been updated since 2012, possibly 382 
indicating that it has been dropped for further research.  Three oxazolidones currently in clinical 383 
trials including MRX-I (MicuRx Pharmacueticals, USA) in phase 3 studies for the treatment of skin 384 
and soft tissue infections.  The remaining two compounds, radezolid and LCB01 0371, are in 385 
phase 2.  Radezolid (Melinta Therapeutics, USA) has demonstrated activity against Gram-negative 386 
infections and only for Haemophilus influenzae.48  Whilst LCB01 0371 (LegoChem Biosciences, 387 
South Korea) is under investigation for the treatment of Gram-positive infections. 388 
Development of 74 oxazolidinones in AntibioticDB has ceased. One, PNU100592 (Pharmacia 389 
Corp., USA) was being developed for the treatment of MRSA.  This molecule was discontinued 390 
due to its inferior activity when compared with linezolid.  Many other oxazolidinones were 391 
discontinued due to high levels of toxicity.  Utilisation of this molecular scaffold to reduce toxicity 392 
may represent an avenue for the development of novel protein synthesis inhibitors with reduced 393 
propensity to select for resistance.  Interestingly, when combined with quinolones, the combination 394 
includes Gram-negative bacteria in the spectrum of activity.49 395 
Pleuromutilins (Ten in AntibioticDB) 396 
Pleuromutilins inhibit the 50S ribosomal subunit; retapamulin, was approved for human use in 397 
2007,50 but, it has been difficult to develop compounds for systemic use,50 mainly due to difficult 398 
peptide chemistry.  Nabriva Therapuetics, Austria, has five candidate compounds in research and 399 
development with one, lefamulin (BC 3781), progressed to phase 3.  Lefamulin is under 400 
development for the treatment of acute bacterial skin and skin structure infections, community-401 
acquired bacterial pneumonia and hospital-acquired bacterial pneumonia/ventilator-associated 402 
bacterial pneumonia.51, 52 403 
Polymyxins (Two in AntibioticDB and one polymyxin analogue) 404 
Polymyxins are produced by non-ribosomal peptide synthetases in Gram-positive soil bacteria 405 
such as Paenibacillus polymyxa.53  They have selective activity against Gram-negative bacteria, 406 
	targeting the lipid A component of the outer membrane.54  Currently, the only polymyxin in clinical 407 
use is polymyxin E (colistin), but, due to high incidence of nephrotoxicity,55 colistin is administered 408 
as an agent of last resort against infections by multi-drug resistant bacteria, such as A. baumannii.  409 
The two polymyxins in pre-clinical development and listed in AntibioticDB are NAB-739 and CA-410 
824, which are being developed by Northern Antibiotics (Finland) and Cantab Anti-infectives, 411 
respectively. 412 
 413 
Quinolones, Fluoroquinolones and Other Topoisomerase Inhibitors (146 in AntibioticDB) 414 
The targets for topoisomerase inhibitors in bacteria are DNA gyrase and DNA topoisomerase IV, 415 
which are enzymes that regulate bacterial DNA supercoiling and relaxation.56  There are currently 416 
five fluoroquinolones in AntibioticDB undergoing active research and development, four are in 417 
clinical studies.  Following two successful phase 3 studies, known as PROCEED, a ‘new drug 418 
authorisation’ for delafloxacin (Melinta Therapeutics, USA and Abbott) was submitted in October 419 
2016 for the treatment of gonococcal, skin and soft tissue infections.  Zabofloxacin (Dong Wha 420 
Pharmaceuticals, South Korea) is in phase 3 for the treatment of community-acquired bacterial 421 
pneumonia and quinolone-non-susceptible gonorrhoea.  Finafloxacin (MerLion Pharmaceuticals, 422 
Germany) has been licensed topically for the treatment of otitis externa.  An oral formulation 423 
continues through phase 2 clinical studies for the management of urinary tract, intra-abdominal 424 
and, skin and soft tissue infections.  Nemonoxacin (TaiGen Biotechnology Co., Taiwan) a non-425 
fluorinated quinolone is currently in phase 357 and has promising broad-spectrum activity targeting 426 
a variety of infections including vancomycin-non-susceptible MRSA. 427 
There are 114 discontinued quinolones and fluoroquinolones documented in AntibioticDB.  428 
Research and development into many of these agents was discontinued due to toxicity, although 429 
some agents were discontinued due to financial constraints.  MCB 3382, a fluoroquinolone–430 
oxalidinone hybrid, was in development by Morphachem AG before the company merged with 431 
Biovertis AG, leading to the discontinuation of their antibacterial research programme. 432 
Sideromycins and sidophore antibiotics (eight in AntibioticDB) 433 
	Siderophores are iron chelators, which can be exploited in a number of therapeutic processes.58  434 
Sideromycins are antibiotic moieties covalently linked to siderophores, allowing for their selective 435 
uptake into the bacterium via the native iron transport systems.59  This feature is useful in the 436 
context of Gram-negative bacteria whereby the outer membrane forms a barrier to drug entry, and 437 
the concentration of some antibiotics required for entry into the cell can become toxic to humans.  438 
One such example is cefiderocol a siderophore cephalosporin, which forms a chelation complex in 439 
the presence of iron.  Cefiderocol (Shionogi, Japan) has recently completed phase 3 for multi-drug 440 
resistant Gram-negative infections. 441 
HKI 9924109 (Basilea Pharmaceutica AG, Switzerland) is an ampicillin adduct linked to a synthetic 442 
siderophore.  This compound was discontinued at the preclinical stage due to its inability, even at 443 
high concentrations, to inhibit the growth of non-fermenting Gram-negative bacteria.60  Despite the 444 
shortcomings of some siderophore-antibiotic conjugates, they remain a useful tool for targeted 445 
therapeutics.61  For example, Wencewikz et al62 have reported a siderophore-carbacephalosporin 446 
conjugate that selectively targets A. baumannii. 447 
Streptogramins (Five in AntibioticDB) 448 
Streptogramins are produced by several Streptomyces species and are structurally unique, having 449 
similar mechanisms of action to macrolides and lincosamides, therefore cross resistance is 450 
possible by target modification thus limiting therapeutic use.63  Examples are pristinamycin 1 and 451 
2, which are produced by Streptomyces pristinaespiralis.  There are no streptogramins in active 452 
research and development listed in AntibioticDB. 453 
Streptothricins (one in AntibioticDB) 454 
Streptothricins have broad-spectrum activity against bacteria and fungi;64 their therapeutic potential 455 
has been hampered by toxicity problems, but they have been successfully utilised for the treatment 456 
of infectious diseases in crop plants; streptothricin-type antibiotics have been marketed as 457 
fungicidal agents in China.65  One streptothricin compound in AntibioticDB is LL-AB 664, which 458 
was reported in 1967.66  New streptothricin class antibiotics have been isolated and assessed for 459 
their antimicrobial potential recently, some of these display potent activity against a variety of 460 
bacteria, particularly Mycobacterium tuberculosis.67, 68  If the problem of resistance to these 461 
	compounds and toxicity in humans can be overcome, then they may represent a new avenue for 462 
antibiotic development.  There are no streptothricins in active research and development listed in 463 
AntibioticDB. 464 
Sulphonamides (Two in AntibioticDB) 465 
Sulphonamides are synthetic compounds based on the industrial dye sulfachrysoidine;69 they are 466 
analogues of p-aminobenzoic acid (PABA) and inhibit folic acid biosynthesis via competitive 467 
inhibition of the enzyme dihydropteroate synthetase.70, 71  This competitive inhibition is 468 
bacteriostatic, disrupting DNA synthesis and bacterial growth.  ABEPI 1 and 2 are currently in pre-469 
clinical development.72  Some antibiotics can act as efflux inhibitors and ABEPI 1 and 2 have been 470 
shown to inhibit the efflux activity of the nosocomial bacteria A. baumannii, which allows for 471 
increased accumulation of the antibiotic minocycline, and subsequent susceptibility to the drug. 472 
Tetracyclines (10 in AntibioticDB) 473 
Tetracyclines are broad-spectrum cyclic antibiotics classified into two types: tetracyclines that bind 474 
to the amino-acyl-tRNA acceptor site of the mRNA ribosomal complex, causing disruption of 475 
protein synthesis, and those that demonstrate antibacterial activity via cytotoxic perturbation of the 476 
cytoplasmic membrane.73  Out of the four tetracyclines in active development listed in AntibioticDB, 477 
two are in pre-clinical development, both by Tetraphase Pharmaceuticals, USA, and two are in 478 
phase 3.  The two phase three compounds are omadacycline and eravacycline. Eravacycline 479 
(Tetraphase Pharmaceuticals, USA) has received mixed results from the phase 3 studies ‘IGNITE’.  480 
In IGNITE1, eravacycline demonstrated non-inferiority to ertapenem in the management of 481 
complicated intra-abdominal infections. In IGNITE2, eravacycline showed inferiority to levofloxacin 482 
in the treatment of complicated UTIs.74 483 
The IGNITE2 study protocol authorised intravenous to oral switch and further data analysis has 484 
suggested participants receiving solely eravacycline intravenously had a more favourable 485 
outcome.  As a consequence, there is a suggestion that poor clinical outcomes were observed due 486 
to problems with the oral eravacycline formulations rather than with the parent compound; two 487 
further phase 3 studies (IGNITE3 and IGNITE4) indicated non-inferiority to meropenem in patients 488 
with polymicrobial infections. These were included in the recent NDA application. 489 
	Omadacycline is a semi-synthetic tetracycline being developed by Paratek Pharmaceuticals, 490 
technically classed as a novel aminomethylcycline, the first in its class.75  The newer tetracyclines 491 
appear to avoid active efflux by bacteria and are effective against typical tetracycline-resistant 492 
bacteria.  The mechanism underlying this phenomenon is unknown.75  AntibioticDB contains four 493 
cyclic tetracyclines that have been discontinued for development as antibacterials. 494 
Miscellaneous molecules (121 in AntibioticDB) 495 
A multitude of molecules that do not fit into pre-defined classes of compounds and inhibiting 496 
various bacterial functions have been reported to display antibiotic activity.  The differences of the 497 
structures of these compounds and the commonly used therapeutic classes may provide avenues 498 
to identify novel molecular scaffolds, less prone to degradation by bacterial-resistance 499 
determinants.  While this may not be an option in cases where resistance has been acquired by 500 
target modification, this remains a resource to bring novelty to the antibiotic research pipeline.  501 
Some agents may fit within a class but were not described as such when first reported. 502 
Reasons for discontinuing compounds 503 
Few compounds in the development pipeline become drug candidates and even fewer are 504 
approved for clinical use.  From analysis of the discontinued compounds, most were discontinued 505 
in pre-clinical research (Figure 1).  This is as expected due in part to the large numbers of 506 
analogues that are often discarded for inferior activity.  There are many factors to be considered 507 
before submission of an IND application relating to a promising drug candidate.  These include: in 508 
vitro and in vivo activity (compounds should have non-inferior activity to other compounds and 509 
existing drugs), levels of toxicity, pharmacokinetic profile (e.g. bioavailability, half-life), cross-510 
resistance to other antibiotics or resistance development and commercial reasons.  In reality, few 511 
agents reach the stage where all these data are available, as discovery of a key impeding factor, 512 
e.g. high toxicity, may preclude any further research and development.  The cited reasons for 513 
discontinuation of a particular drug given in AntibioticDB are depicted in Figure 2.  As a result of 514 
the lack of further pursuit when a compound’s poor potential is identified, very few reasons for 515 
discontinuation have been published. 516 
	Thirty-eight compounds are listed in AntibioticDB where evidence for discontinuation of research 517 
was identified as ‘due to commercial reasons’, company acquisition, or the ‘financial circumstances 518 
of the developing company’.  Examples include: the Genaera ‘Magainin program’ (company shut 519 
down), Essential Therapeutics (bankruptcy) and the Cubist pipeline (acquired by MSD).  In these 520 
cases, the rights to company assets can be purchased.  However, for many early stage 521 
compounds, there may not have been a sufficient incentive for these compounds to be purchased.  522 
Therefore, it is possible that certain compounds were overlooked, or in too early a stage of 523 
development, and that these have the potential to be taken to market without optimisation or be 524 
used as intermediates for further analysis and development. 525 
In the last 15 years many large pharmaceutical companies (including Astra-Zeneca, Bristol Myers 526 
Squibb, Eli Lilly and Wyeth) discontinued antibiotic research because their pipelines had no viable 527 
compounds and/or because of economic factors.  To identify novel compounds, European and 528 
American researchers and companies turned to target-based discovery to identify agents with 529 
novel modes of action, whilst Japan tended towards finding derivatives of existing, successful 530 
compounds such as fluoroquinolones and β-lactams.  In using target-based discovery, researchers 531 
encountered many issues with entry of the antibiotics into bacterial cells.  The timeline for antibiotic 532 
discovery is illustrated in Figure 3. 533 
Of those agents with a documented reason for termination of development, approximately 50% 534 
were discontinued due to toxicity.  Many compounds were also discarded where research revealed 535 
resistance, unfavourable pharmacokinetics or poor potency. Interestingly, following investigation 536 
beyond the published literature from the developer, some compounds were discontinued for 537 
“circumstantial reasons”, suggesting that this was not due to unfavourable properties of the 538 
compound.  One example of this is the compound JNJ-17155437, a ketolide antibiotic reported by 539 
Johnson and Johnson.  Research and development into this compound was discontinued around 540 
about the time that questions were raised around another ketolide antibiotic being developed by 541 
the company called telethromycin (Ketek).  This drug was approved by the FDA and said to be one 542 
of the first compounds of its type to circumvent antimicrobial resistance.76  In the year following 543 
initial approval, several deaths were reported due to liver failure in people treated from community-544 
	acquired pneumonia with telethromycin.  The suboptimal safety profile of this drug and the 545 
structurally related JNJ-17155437 may have been the reason for discontinuation of the compound.546 
	Discussion 547 
AntibioticDB was assembled with the intention of generating a platform to facilitate researchers 548 
from academic or industry backgrounds to potentially research and develop previously 549 
discontinued compounds into new antibacterial drugs.  Additionally, it is an accessible source of 550 
information to determine the progress of compounds currently in development.  While there are 551 
databases and publications5, 77-79 describing the properties of compounds and their status, 552 
including the Springer-AdisInsight and Thomson Reuter databases, these are not widely 553 
accessible and some are only available on a paid subscription basis.  Furthermore, AntibioticDB 554 
includes antibacterial compounds no longer in active development, and indicates, where possible, 555 
the reasons why development was discontinued.  To identify the latter, the published literature, 556 
company websites and other databases were interrogated, and individuals with extensive 557 
knowledge interviewed.  It should be noted that for many of the compounds, there is little available 558 
information as they were discontinued in early pre-clinical development and there was no publicly 559 
available information. 560 
Several discontinued antibiotic classes and compounds have been revisited to investigate whether 561 
there is any merit in developing them for medical use.  For instance, in the 1980s daptomycin (LY 562 
146032) was under development by Eli Lilly and Co.; however, in clinical trials, muscle-skeletal 563 
damage was shown, and so development of the compound was discontinued.  In 1997, Cubist 564 
Pharmaceuticals acquired the rights to this drug and after changing the dosing to IV administration 565 
once daily, daptomycin was found to be safe.  It was approved by the FDA and marketed in 566 
2003.80  Secondly, pleuromutilins such as tiamulin have been previously used in veterinary 567 
medicine, but there is now the prospect of developing them as therapies for humans.  GSK 568 
developed retapamulin (Altabax) and currently Nabriva is developing a further three compounds,81 569 
including lefamulin, which is a candidate for treatment of community-acquired pneumonia.  A third 570 
drug candidate is iclaprim.  In 2009, FDA rejected Arpida’s application on the grounds of 571 
incomplete data to demonstrate efficacy.  In April 2015, the FDA accepted the proposal of two 572 
further phase 3 trials by Motif Bio who gained the rights to the drug and plan to continue its 573 
development.82  These examples indicate that there can be merit in reinvestigating discontinued 574 
	antibiotics for future development, and AntibioticDB will provide a platform to facilitate this.  There 575 
is a possibility that with the progression of synthetic chemistry and other areas of science, cross-576 
disciplinary approaches may be able to optimise some old compounds to remove unfavourable 577 
characteristics and make them more useful in future.83  For these agents to be developed there will 578 
need to be a financial incentive. 579 
There is also the need to consider the target patient of new antibiotics.  Some compounds were 580 
discontinued due to toxicity, however certain compounds e.g. colistin, despite presenting toxicity 581 
issues could progress further through the drug development pipeline.  However, with the 582 
understanding of AMR, it is probable that many new antibiotics will not be widely used.  Many will 583 
be kept as reserve agents for compassionate designation usage, i.e. usage in mitigating 584 
circumstances, where few other therapeutic options are available; this means that the regulatory 585 
authorities may allow companies to provide experimental drugs to people outside of clinical trials.  586 
Whilst re-investigating discontinued compounds is a possibility, there are some complications.  For 587 
instance, the expertise in synthesising certain compounds or their documentation may no longer 588 
be available.  This is likely for those companies that have ceased their research in this area or 589 
become bankrupt.  In these cases, many derivatives may have been synthesised from a promising 590 
parental compound which demonstrated toxicity or other unfavourable properties.  If the 591 
information about these derivatives has been lost, reinvestment is high risk, which highlights the 592 
importance of an open-access approach to pre-clinical and clinical development of therapeutic 593 
drugs.  Another complication is that some discontinued compounds may not have been patented 594 
as a drug but as an intermediate.  If the patent is still valid, another organisation synthesising 595 
derivatives, may infringe the patent.  Finally, a company investigating old compounds will, to 596 
receive regulatory approval, ultimately need to be able to ensure a steady supply of drug. 597 
While the cases of daptomycin and the pleuromutilins show that ‘reviving’ old antibiotics is possible 598 
and can be successful, it must be considered whether this is a viable path of antibiotic research 599 
and development for other discontinued compounds.  It is important to note that the currently 600 
prevalent bacteria have evolved and disseminated because of selection by antibiotics in current 601 
clinical use. Therefore, further development of old and/or compounds of the same class may not 602 
	be productive as resistance mechanisms active against these agents may already be widely 603 
disseminated.  Many of the discontinued compounds in AntibioticDB will not have been tested 604 
against current clinical isolates, suggesting a potential difference in efficacy from when they were 605 
first screened.  Nonetheless, compounds that demonstrate a novel mode of action may evade 606 
current resistance issues and thus could be clinically useful.  This was the case for daptomycin 607 
and the pleuromutilins. 608 
The UK AMR Review has questioned the sustainability of the current R&D pipeline for antibiotic 609 
development2 and indicated that for a sustainable future of antibiotic development 15 new 610 
antibacterials need to be developed every 10 years.  The AMR review also noted that novelty is a 611 
direct issue for today’s antibiotic development, with no new antibiotic drug classes being developed 612 
in the past 30 years (since the lipopeptide daptomycin in 1986).  Currently there are 152 active 613 
pre-clinical compounds listed in the AntibioticDB.  The attrition rate in drug development is well 614 
known and based on data provided by the Review on AMR on success rates it is possible that 615 
three may be approved for human use by 2025.2  This demonstrates a possible gap of 12 616 
licensable compounds over 10 years.  Data from the Review on AMR suggests the number of pre-617 
clinical compounds that require testing in order to generate 15 licensed medicines is approximately 618 
590, a shortfall of 440 compounds (Figure 4). 619 
Academia has an important part to play in the fight against antimicrobial-resistant infections, with 620 
the need for innovation in the field and subsequent development of antibiotics with novel 621 
mechanisms of action at its greatest.  This alone however is not enough, and only with 622 
collaboration between academia, SMEs, big pharma, funding bodies, and governments can this 623 
goal be achieved.  AntibioticDB, described herein provides a valuable tool for anyone involved with 624 
antibiotic discovery, research and development.  By providing a history of compounds that have 625 
been discontinued with the current status of antibiotic discovery, research and development 626 
(including pre-clinical development), AntibioticDB will enable academia and industry alike to 627 
explore previously discontinued antibiotics for the treatment of the drug-resistant infections we are 628 
faced with today.  AntibioticDB is an interactive database; therefore, we call upon all involved in 629 
	this field be it pharmaceutical companies, university groups or individuals, to help to continue to 630 
populate AntibioticDB.  631 
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	Legends to Figures 660 
Figure 1.  The stages at which antibiotic compounds in this database were discontinued for 661 
development (values from AntibioticDB 31st March 2017).  As a disproportionate number of 662 
compounds are discontinued at the pre-clinical stage, the y-axis is split to reflect this.  I: phase one 663 
clinical trials; II: phase two clinical trials; III: phase three clinical trials; IV: phase four clinical trials. 664 
 665 
Figure 2. The reasons identified for termination of compound development (values from 666 
AntibioticDB 31st March 2017). Unknown; Toxicity, either in animals or humans; Inferior: studies 667 
showed inferiority to comparator compound.  That may have been a marketed or study compound; 668 
Resistance, resistance acquired to compound within studies; Commercial, includes bankruptcy, 669 
mergers, closing R&D facilities; Clinical results, unfavourable outcomes; Pharmacokinetics, 670 
unsuitable parameters; Pharmacodynamics, unsuitable parameters. 671 
 672 
Figure 3. A timeline of the discovery of the major classes of antibiotics.  From 1986 to 2017, 673 
regulatory authorities have approved no new class of antibiotics; this has been termed the 674 
‘discovery void’.84 675 
 676 
Figure 4. Antibiotic discovery, research and developmental pipeline (values from AntibioticDB 31st 677 
March 2017).  The X-axis represents the average time in years in takes to progress a compound 678 
through each clinical stage, with the final stage, Post-marketing surveillance, taking an 679 
undetermined amount of time.  The percentage between each clinical stage states on average how 680 
many compounds will make it to the next stage of clinical development is based on the data 681 
provided in the Review on Antimicrobial Resistance.2 682 
  683 
	Table 1: Phases of drug development 684 
Phase Comment 
1 Typically consist of a small group (20-100) studies in healthy volunteers in a controlled 
setting to test the compound’s pharmacokinetics, toxicity and pharmacology; goal is to 
determine the maximum tolerated dose range that can be safely used; typically 33% of 
drugs in phase 1 proceed to phase 2. 
2 Expand patient numbers to a few hundred; used to understand the compound’s dosing 
requirements, efficacy and adverse effects; typically 59% continue to phase 3 
3 Large, randomised, controlled, multicentre studies in which treatment by the study 
compound is usually compared against the currently accepted ‘gold standard’; 
success in phase 3 is much higher than in earlier phases, typically ~76%; mostly due 
to the stringency of previous trials.  Phase 3 provides clinical data necessary to file for 
a new drug application (NDA) potential marketing authorization applicant (MAA); 
application is usually submitted when there is sufficient data on the 
safety/pharmacology of the compound; typically ~80% of antimicrobial compounds 
awaiting approval are granted an NDA 
4 Often termed as post-marketing surveillance; the compound is formulated as a 
medicine and been given full marketing approval; data is usually collected on the 
safety profile of the drug.  Further research can be initiated to test the drug profile in 
different disease states, for combination therapies, alternative delivery systems and 
different subject groups if the company chooses to do so.  Medicines can be 
discontinued or withdrawn at this stage if it becomes apparent that the medicine has 
intolerable adverse effects or is unsuitable for clinical practice 
 685 
  686 
	Table 2: AntibioticDB terms 687 
Term Definition 
1. Drug name Current generic name of the compound; alternate or past names are 
indicated in brackets 
2. Drug class Antibiotics can be classified in two ways: (1) by chemical structure e.g. a 
fluoroquinolone, and (2) based on the mechanism or target of the compound 
e.g. a topoisomerase inhibitor; in AntibioticDB, compounds are classified by 
both methods where applicable 
3. Development 
phase 
The highest development phase a compound has reached as of 30 March 
2017, for example pre-clinical, phase 1, 2, 3, 4, or marketed 
4. Organisation Represents the party or individual that has been listed as the lead discoverer 
or developer of the compound; encompasses large pharmaceutical 
companies, university groups or individuals. 
5. Gram-negative 
activity 
Indicates a compound with activity against Gram-negative bacteria which 
is/was in the process of being developed to target these bacteria; includes 
compounds with a broad spectrum but are targeted to these bacteria during 
their development 
6. Gram-positive 
activity 
Indicates a compound with activity against Gram-positive bacteria which 
is/was in the process of being developed to target these bacteria 
7. Combination 
agents 
Indicates agents used in combination with other antibiotics or other 
compounds that enhance antibiotic efficacy of the compound in question 
8. Low 
propensity 
Criteria for selection of compounds with ‘propensity to select resistant 
mutants’ was only applied if data were available showing that bacteria had 
been exposed to the compound for the purpose of detecting bacterial 
resistance, or if resistance had been observed during clinical trial; where no 
data was available, this parameter was left blank in the database 
9. Mechanism of 
action 
The site/s of interaction of the compound with the bacterium e.g. cell wall 
inhibitor, DNA gyrase inhibitor 
10. Target 
bacteria 
If a compound has a broad spectrum of activity, comparative details of its 
efficacy against Gram-positive and Gram-negative organisms are provided 
11. Current 
status 
Gives information on the compound drug: active research (A) or inactive (I) 
12. Reason 
antibiotic not 
developed 
Indicates why a compound failed to advance further or was retracted from 
market.  To gather this information, the Springer database ‘AdisInsight’ was 
used; Dr Lynn L. Silver, Dr Jared A. Silverman, Dr Ursula Theuretzbacher 
and Dr Glenn Tillotson provided additional information.  Blank fields in this 
section indicate that the original author, or authors of subsequent pieces of 
work, has given no reason as to why a compound may have been dropped, 
which was often found to be the case for compounds predating 1990 
13. Citation Indicates the journal article/conference abstract that the compound was first 
described; provided as a web address and/or reference.  If more than one 
source is cited brackets containing the number refers to the reference from 
which the information was derived.  Where possible the first reference will be 
the first description of the drug (e.g. ICAAC abstract) and the second will be a 
publication that gives the broadest overview and/or most information 
regarding the compound 
 688 
	Bracketed compounds in AntibioticDB represent the most promising compounds discussed of a 689 
series of analogues.  Information on the inferior derivative compounds can often be found in the 690 
reference provided. 691 
  692 
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